Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 3;19(12):e0314876.
doi: 10.1371/journal.pone.0314876. eCollection 2024.

Diagnostic potential of genomic blood biomarkers of pulmonary fibrosis in a prospective cohort

Affiliations

Diagnostic potential of genomic blood biomarkers of pulmonary fibrosis in a prospective cohort

Daniel He et al. PLoS One. .

Abstract

Fibrotic interstitial lung diseases (ILDs) result from excessive deposition of extracellular matrix (ECM) proteins in the lung, causing irreversible damage to the lung architecture. Clinical management of ILDs differs depending on the diagnosis, but differentiation between subtypes can be difficult and better clinical biomarkers are needed. In this study, we use a 166-gene NanoString assay to investigate whether there are ILD subtype-specific transcripts in whole blood. We identified one transcript, killer cell lectin like receptor 1 (KLRF1), as differentially expressed between idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated ILD (SSc-ILD), and identified two transcripts (VCAN, LTK) associated with IPF expression against other ILD subtypes. These findings were validated by examining their expression in ILD lung, with KLRF1 expression significantly higher in SSc-ILD compared to IPF and hypersensitivity pneumonitis (HP) samples. Taken together, this pilot study provides support for the use of the peripheral transcriptome in identifying diagnostic biomarkers of ILD with biological relevance.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Expression of KLRF1, LTK, VCAN in whole blood (log2 RNA expression) or lung tissue microarray sections (H-Score) containing samples from patients with idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Statistical significance of blood RNA expression was determined using differential expression analysis via ‘limma’ and corrected using false discovery rate (FDR), with statistical significance indicated by FDR<0.05 (***). To determine statistical significance of H-scores, a linear mixed-effects model was fitted and pairwise comparisons between diagnoses were performed and corrected for using Tukey’s post-hoc adjustment (* denotes p<0.05).
Fig 2
Fig 2. Histological staining of tissue microarray cores taken from donor lungs of patients with idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Arrows indicate areas of positive staining.

References

    1. Renzoni EA, Poletti V, Mackintosh JA. Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia? The Lancet. 2021. Oct 16;398(10309):1437–49. doi: 10.1016/S0140-6736(21)01961-9 - DOI - PubMed
    1. Spagnolo P, Ryerson CJ, Putman R, Oldham J, Salisbury M, Sverzellati N, et al.. Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. The Lancet Respiratory Medicine. 2021. Sep 1;9(9):1065–76. doi: 10.1016/S2213-2600(21)00017-5 - DOI - PubMed
    1. Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C, et al.. Biomarker signatures for progressive idiopathic pulmonary fibrosis. Eur Respir J. 2022. Mar;59(3):2101181. doi: 10.1183/13993003.01181-2021 - DOI - PubMed
    1. Axelsson GT, Gudmundsson G, Pratte KA, Aspelund T, Putman RK, Sanders JL, et al.. The Proteomic Profile of Interstitial Lung Abnormalities. Am J Respir Crit Care Med. 2022. Aug 1;206(3):337–46. doi: 10.1164/rccm.202110-2296OC - DOI - PMC - PubMed
    1. Bowman WS, Newton CA, Linderholm AL, Neely ML, Pugashetti JV, Kaul B, et al.. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir Med. 2022. Jun;10(6):593–602. doi: 10.1016/S2213-2600(21)00503-8 - DOI - PMC - PubMed

MeSH terms